---
figid: PMC4149909__nihms597526f2
figlink: /pmc/articles/PMC4149909/figure/F2/
number: F2
caption: 'Gaps in conventional treatment of heart failure include deranged β-AR signaling,
  distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic dysfunction,
  and cell death. For each of these gaps, the molecular signaling pathways involved
  and potential gene therapy targets (depicted in color) are shown. (a) β-AR signaling:
  overexpression of the β2-AR, overexpression of AC VI, and inhibition of GRK2 by
  its C-terminal domain βARKct are all aimed at resensitizing the β-AR–G-protein–Ac
  interactome. (b) Ca2+ cycling: overexpression of SERCA2a, S100A1, or a dominant
  negative form of PLN or an shPLN are aimed at normalization of intracellular Ca2+
  handling. S100A1 also stabilizes the RyR, thereby reducing arrhythmogenic vulnerability.
  I-1 overexpression inhibits PP1, thereby also activating SERCA2a. (c) Diastolic
  dysfunction: overexpression of SERCA2a and S100A reduce diastolic cytosolic Ca2+
  levels and increase SR Ca2+ reuptake, thereby improving diastolic relaxation parameters.
  Overexpression of parvalbumin, an intracellular Ca2+ sink, leads to an energy-independent
  selective amelioration of diastolic dysfunction. (d) cell survival: β2-AR exerts
  antiapoptotic effects through the Gi-protein-mediated activation of the phosphatidylinositol-3′-kinase
  (PI3K)/Akt cell-survival pathway. Overexpression of a constitutively active form
  of Akt or PI3K and the abolishment of GRK2-mediated inhibition of Akt activate the
  survival pathway in heart failure. AC VI, adenylyl cyclase VI; β-AR, β-adrenergic
  receptor; βARKct, C-terminal domain of GRK2; GRK2, G-protein-coupled receptor kinase
  2; I-1, inhibitor-1; PI3K, phosphatidylinositol-3′-kinase; PLN, phospholamban; PP1,
  protein phosphatase type 1; RyR, ryanodine receptor; SERCA2a, sarcoplasmic reticulum
  Ca2+ ATPase; shPLN, short hairpin PLN; SR, sarcoplasmic reticulum.'
pmcid: PMC4149909
papertitle: 'Gene therapy targets in Heart Failure: the Path to translation.'
reftext: PWJ Raake, et al. Clin Pharmacol Ther. ;90(4):542-553.
pmc_ranked_result_index: '147500'
pathway_score: 0.7604687
filename: nihms597526f2.jpg
figtitle: Gaps in conventional treatment of heart failure include deranged Beta-AR
  signaling, distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic dysfunction,
  and cell death
year: ''
organisms:
- Homo sapiens
ndex: 6c3518b7-df2e-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4149909__nihms597526f2.html
  '@type': Dataset
  description: 'Gaps in conventional treatment of heart failure include deranged β-AR
    signaling, distorted Ca2+ cycling with depletion of SR Ca2+ levels, diastolic
    dysfunction, and cell death. For each of these gaps, the molecular signaling pathways
    involved and potential gene therapy targets (depicted in color) are shown. (a)
    β-AR signaling: overexpression of the β2-AR, overexpression of AC VI, and inhibition
    of GRK2 by its C-terminal domain βARKct are all aimed at resensitizing the β-AR–G-protein–Ac
    interactome. (b) Ca2+ cycling: overexpression of SERCA2a, S100A1, or a dominant
    negative form of PLN or an shPLN are aimed at normalization of intracellular Ca2+
    handling. S100A1 also stabilizes the RyR, thereby reducing arrhythmogenic vulnerability.
    I-1 overexpression inhibits PP1, thereby also activating SERCA2a. (c) Diastolic
    dysfunction: overexpression of SERCA2a and S100A reduce diastolic cytosolic Ca2+
    levels and increase SR Ca2+ reuptake, thereby improving diastolic relaxation parameters.
    Overexpression of parvalbumin, an intracellular Ca2+ sink, leads to an energy-independent
    selective amelioration of diastolic dysfunction. (d) cell survival: β2-AR exerts
    antiapoptotic effects through the Gi-protein-mediated activation of the phosphatidylinositol-3′-kinase
    (PI3K)/Akt cell-survival pathway. Overexpression of a constitutively active form
    of Akt or PI3K and the abolishment of GRK2-mediated inhibition of Akt activate
    the survival pathway in heart failure. AC VI, adenylyl cyclase VI; β-AR, β-adrenergic
    receptor; βARKct, C-terminal domain of GRK2; GRK2, G-protein-coupled receptor
    kinase 2; I-1, inhibitor-1; PI3K, phosphatidylinositol-3′-kinase; PLN, phospholamban;
    PP1, protein phosphatase type 1; RyR, ryanodine receptor; SERCA2a, sarcoplasmic
    reticulum Ca2+ ATPase; shPLN, short hairpin PLN; SR, sarcoplasmic reticulum.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ADCY4
  - AKT2
  - ADCY10
  - PLN
  - ADCY3
  - ADCY6
  - ADCY2
  - ADCY8
  - ADCY9
  - ADCY5
  - GJA8
  - AKT3
  - PRKAR1A
  - CASP7
  - CASP8
  - ADCY1
  - CASP1
  - CASP3
  - CASP4
  - CASP5
  - ADCY7
  - CASP6
  - GRK2
  - TLX2
  - PRKACG
  - CASP9
  - CASP10
  - AKT1
  - BAD
  - RYR2
  - PRKAR2B
  - AR
  - CAD
  - PRKACA
  - NOS3
  - PRKAR1B
  - CASP2
  - CASP12
  - PRKACB
  - PRKAR2A
  - CASP14
genes:
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY4
  entrez: '196883'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY10
  entrez: '55811'
- word: PLN
  symbol: PLN
  source: hgnc_symbol
  hgnc_symbol: PLN
  entrez: '5350'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY3
  entrez: '109'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY6
  entrez: '112'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY2
  entrez: '108'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY8
  entrez: '114'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY9
  entrez: '115'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY5
  entrez: '111'
- word: Cae.
  symbol: CAE
  source: hgnc_prev_symbol
  hgnc_symbol: GJA8
  entrez: '2703'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP7
  entrez: '840'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP8
  entrez: '841'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY1
  entrez: '107'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP1
  entrez: '834'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP3
  entrez: '836'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP4
  entrez: '837'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP5
  entrez: '838'
- word: AC
  symbol: AC
  source: bioentities_symbol
  hgnc_symbol: ADCY7
  entrez: '113'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP6
  entrez: '839'
- word: GRK2
  symbol: GRK2
  source: hgnc_symbol
  hgnc_symbol: GRK2
  entrez: '156'
- word: NCX
  symbol: NCX
  source: hgnc_alias_symbol
  hgnc_symbol: TLX2
  entrez: '3196'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP9
  entrez: '842'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP10
  entrez: '843'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: Bad
  symbol: BAD
  source: hgnc_symbol
  hgnc_symbol: BAD
  entrez: '572'
- word: RYR2
  symbol: RYR2
  source: hgnc_symbol
  hgnc_symbol: RYR2
  entrez: '6262'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: B,-AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: Cad.
  symbol: CAD
  source: hgnc_symbol
  hgnc_symbol: CAD
  entrez: '790'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: eNOS
  symbol: eNOS
  source: hgnc_alias_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP2
  entrez: '835'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP12
  entrez: '100506742'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: Caspase
  symbol: Caspase
  source: bioentities_symbol
  hgnc_symbol: CASP14
  entrez: '23581'
chemicals: []
diseases: []
figid_alias: PMC4149909__F2
redirect_from: /figures/PMC4149909__F2
figtype: Figure
---
